-
Non-invasive imaging of beta cell mass: a quantitative analysis.
Diabetes Technol TherSweet IR, Cook DL, Lernmark A, Greenbaum CJ, Krohn KA -
Conformation-dependent GAD65 autoantibodies in diabetes.
DiabetologiaLuo D, Gilliam LK, Greenbaum CJ, Bekris L, Hampe CS, Daniels T, Richter W, Marcovina SM, Rolandsson O, Landin-Olsson M, Kockum I, Lernmark A -
Male sex increases the risk of autoimmunity but not type 1 diabetes.
Diabetes CareKrischer JP, Cuthbertson DD, Greenbaum CJ, Diabetes Prevention Trial Type 1 Study Group. -
GAD65-specific CD4+ T-cells with high antigen avidity are prevalent in peripheral blood of patients with type 1 diabetes.
DiabetesReijonen H, Mallone R, Heninger AK, Laughlin EM, Kochik SA, Falk B, Kwok WW, Greenbaum CJ, Nepom GT -
Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus--a new surrogate measure of non-progression?
Pediatr DiabetesSchatz D, Cuthbertson D, Atkinson M, Salzler MC, Winter W, Muir A, Silverstein J, Cook R, Maclaren N, She JX, Greenbaum CJ, Krischer JP -
Autoimmunity to islet proteins in children diagnosed with new-onset diabetes.
J Clin Endocrinol MetabBrooks-Worrell BM, Greenbaum CJ, Palmer JP, Pihoker C -
The case for intravenous arginine stimulation in lieu of mixed-meal tolerance tests as outcome measure for intervention studies in recent-onset type 1 diabetes.
Diabetes CareGreenbaum CJ, Seidel K, Pihoker C -
Future intervention trials in type 1 diabetes.
Diabetes CareWilkin T, Ludvigsson J, Greenbaum CJ, Palmer JP, Becker D, Bruining J -
Systematic screening of potential beta-cell imaging agents.
Biochem Biophys Res CommunSweet IR, Cook DL, Lernmark A, Greenbaum CJ, Wallen AR, Marcum ES, Stekhova SA, Krohn KA -
C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.
DiabetesPalmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW -
Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes.
DiabetesGreenbaum CJ, Harrison LC, Immunology of Diabetes Society. -
Macrophages from high-risk HLA-DQB1*0201/*0302 type 1 diabetes mellitus patients are hypersensitive to lipopolysaccharide stimulation.
Scand J ImmunolPlesner A, Greenbaum CJ, Gaur LK, Ernst RK, Lernmark A -
Type 1 diabetes intervention trials: what have we learned? A critical review of selected intervention trials.
Clin ImmunolGreenbaum CJ -
Insulin resistance in type 1 diabetes.
Diabetes Metab Res RevGreenbaum CJ -
Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose.
DiabetesGreenbaum CJ, Prigeon RL, D'Alessio DA
